Patient Access to Affordable Medicines: How a Renegotiated NAFTA Could Keep Drug Prices High

Friday, September 14, 2018
Noon–1:00 p.m.

1310 Longworth House Office Building
Committee on House Administration Hearing Room

On August 31, President Trump notified Congress of his intent to sign a trade agreement with Mexico. This agreement could have a significant impact on the United States’ economy, including prescription drug pricing and the emerging biosimilars market.

Please join the Association for Accessible Medicines (AAM) for a briefing to discuss the proposed NAFTA agreement, its impact on rising prescription drug prices and recommendations for a stronger agreement.

Panelists include:

Jeff Francer (Moderator)
Senior Vice President and General Counsel, Association for Accessible Medicines

Marcie McClintic Coates
Head of Global Policy, Mylan

David Mitchell
President and Founder, Patients for Affordable Drugs

Leigh Purvis
Director, Health Services Research, AARP

This briefing has been designed to comply with House and Senate ethics rules. Lunch will be provided.

To RSVP, contact Lindsey Novak

 

Generics

are a proven prescription for a healthier society.

Generic and biosimilar medicines make it easier and more affordable for patients to live healthier lives.

AAM Tweets